Page last updated: 2024-08-17

perflutren and Wet Macular Degeneration

perflutren has been researched along with Wet Macular Degeneration in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's9 (81.82)24.3611
2020's2 (18.18)2.80

Authors

AuthorsStudies
Han, JM; Kang, HG; Kim, JH; Kim, KL; Kim, M; Kim, MS; Kim, SW; Lee, CS; Lee, JY; Park, SJ; Woo, SJ1
Lee, K; Park, YG; Park, YH1
Chang, W; Garg, SJ; Gupta, SA; Ho, AC; Hsu, J; Maturi, R; Regillo, CD; Sivalingam, A1
Cho, HJ; Han, JI; Kim, HS; Kim, JH; Kim, JW; Koh, KM; Lee, TG; Lew, YJ1
Byeon, SH; Lee, JM; Shin, JY1
Cereda, MG; de Jong, JH; Faridpooya, K; van Meurs, JC; van Velthoven, ME; van Zeeburg, EJ; Vermeer, KA1
Barr, CC; Fassbender, JM; Schaal, S; Sherman, MP1
Kitagawa, Y; Mori, R; Shimada, H; Tanaka, K; Yuzawa, M1
Bindra, MS; de Silva, SR1
Kim, YM; Koh, HJ; Lee, SJ1
Jackson, TL; Liazos, E; McHugh, D; Papavasileiou, E; Steel, DH1

Trials

1 trial(s) available for perflutren and Wet Macular Degeneration

ArticleYear
INTRAVITREAL VERSUS SUBRETINAL ADMINISTRATION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR COMBINED WITH GAS FOR ACUTE SUBMACULAR HEMORRHAGES DUE TO AGE-RELATED MACULAR DEGENERATION: An Exploratory Prospective Study.
    Retina (Philadelphia, Pa.), 2016, Volume: 36, Issue:5

    Topics: Acute Disease; Combined Modality Therapy; Endotamponade; Fibrinolytic Agents; Fluorocarbons; Humans; Injections, Intraocular; Intravitreal Injections; Prospective Studies; Recombinant Proteins; Retinal Hemorrhage; Tissue Plasminogen Activator; Tomography, Optical Coherence; Visual Acuity; Vitrectomy; Wet Macular Degeneration

2016

Other Studies

10 other study(ies) available for perflutren and Wet Macular Degeneration

ArticleYear
MACULAR HOLE ASSOCIATED WITH AGE-RELATED MACULAR DEGENERATION: Pathogenesis and Surgical Outcomes.
    Retina (Philadelphia, Pa.), 2021, Oct-01, Volume: 41, Issue:10

    Topics: Aged; Endotamponade; Female; Fluorocarbons; Geographic Atrophy; Humans; Male; Middle Aged; Retinal Perforations; Retrospective Studies; Silicone Oils; Sulfur Hexafluoride; Tomography, Optical Coherence; Treatment Outcome; Visual Acuity; Vitrectomy; Wet Macular Degeneration

2021
VISUAL PROGNOSIS AFTER PNEUMATIC DISPLACEMENT OF SUBMACULAR HEMORRHAGE ACCORDING TO AGE-RELATED MACULAR DEGENERATION SUBTYPES.
    Retina (Philadelphia, Pa.), 2020, Volume: 40, Issue:12

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Choroidal Neovascularization; Endotamponade; Female; Fluorescein Angiography; Fluorocarbons; Humans; Intravitreal Injections; Male; Middle Aged; Prognosis; Retinal Hemorrhage; Retrospective Studies; Supine Position; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration

2020
Management of thick submacular hemorrhage with subretinal tissue plasminogen activator and pneumatic displacement for age-related macular degeneration.
    American journal of ophthalmology, 2014, Volume: 157, Issue:6

    Topics: Aged; Aged, 80 and over; Air; Angiogenesis Inhibitors; Combined Modality Therapy; Endotamponade; Female; Fibrinolytic Agents; Fluorescein Angiography; Fluorocarbons; Humans; Injections, Intraocular; Male; Middle Aged; Prone Position; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tissue Plasminogen Activator; Tomography, Optical Coherence; Treatment Outcome; Vascular Endothelial Growth Factor A; Visual Acuity; Vitrectomy; Wet Macular Degeneration

2014
Intravitreal ranibizumab injections with and without pneumatic displacement for treating submacular hemorrhage secondary to neovascular age-related macular degeneration.
    Retina (Philadelphia, Pa.), 2015, Volume: 35, Issue:2

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Coloring Agents; Combined Modality Therapy; Endotamponade; Female; Fluorescein Angiography; Fluorocarbons; Humans; Indocyanine Green; Intravitreal Injections; Male; Middle Aged; Ranibizumab; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration

2015
Anti-vascular endothelial growth factor with or without pneumatic displacement for submacular hemorrhage.
    American journal of ophthalmology, 2015, Volume: 159, Issue:5

    Topics: Aged; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Bevacizumab; Combined Modality Therapy; Endotamponade; Female; Fluorescein Angiography; Fluorocarbons; Follow-Up Studies; Humans; Intravitreal Injections; Male; Ranibizumab; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration

2015
TISSUE PLASMINOGEN ACTIVATOR FOR SUBFOVEAL HEMORRHAGE DUE TO AGE-RELATED MACULAR DEGENERATION: Comparison of 3 Treatment Modalities.
    Retina (Philadelphia, Pa.), 2016, Volume: 36, Issue:10

    Topics: Aged; Aged, 80 and over; Endotamponade; Exudates and Transudates; Female; Fibrinolytic Agents; Fluorocarbons; Fovea Centralis; Humans; Intravitreal Injections; Male; Retinal Hemorrhage; Retrospective Studies; Sulfur Hexafluoride; Tertiary Care Centers; Tissue Plasminogen Activator; Tomography, Optical Coherence; Visual Acuity; Vitrectomy; Wet Macular Degeneration

2016
Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
    Ophthalmology, 2016, Volume: 123, Issue:6

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Choroidal Neovascularization; Combined Modality Therapy; Endotamponade; Female; Fibrinolytic Agents; Fluorescein Angiography; Fluorocarbons; Humans; Intravitreal Injections; Male; Middle Aged; Polyps; Prone Position; Prospective Studies; Ranibizumab; Retinal Hemorrhage; Tissue Plasminogen Activator; Tomography, Optical Coherence; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration

2016
Early treatment of acute submacular haemorrhage secondary to wet AMD using intravitreal tissue plasminogen activator, C3F8, and an anti-VEGF agent.
    Eye (London, England), 2016, Volume: 30, Issue:7

    Topics: Acute Disease; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Bevacizumab; Endotamponade; Female; Fibrinolytic Agents; Fluorocarbons; Humans; Intravitreal Injections; Male; Ranibizumab; Retinal Hemorrhage; Retrospective Studies; Secondary Prevention; Tissue Plasminogen Activator; Vascular Endothelial Growth Factor A; Visual Acuity; Wet Macular Degeneration

2016
Gas-assisted release of vitreomacular adhesion in wet age-related macular degeneration.
    Retina (Philadelphia, Pa.), 2011, Volume: 31, Issue:10

    Topics: Fluorocarbons; Humans; Intraocular Pressure; Intravitreal Injections; Prone Position; Retinal Diseases; Risk Factors; Tissue Adhesions; Tomography, Optical Coherence; Vitreous Body; Vitreous Detachment; Wet Macular Degeneration

2011
Intravitreal tissue plasminogen activator, perfluoropropane (C3F8), and ranibizumab or photodynamic therapy for submacular hemorrhage secondary to wet age-related macular degeneration.
    Retina (Philadelphia, Pa.), 2013, Volume: 33, Issue:4

    Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Choroid Diseases; Combined Modality Therapy; Endotamponade; Female; Fibrinolytic Agents; Fluorocarbons; Humans; Intravitreal Injections; Male; Middle Aged; Photochemotherapy; Polyps; Prone Position; Ranibizumab; Retinal Hemorrhage; Retrospective Studies; Tissue Plasminogen Activator; Tomography, Optical Coherence; Visual Acuity; Wet Macular Degeneration

2013